Knowledge HQ

This study utilized the Tapestri platform to characterize CRISPR-Cas9 engineered CD8+ T cells targeting TRAC and TRBC loci. Activated T cells were nucleofected and cultured in 24-well G-Rex plates for 7 days. The analysis quantified on-target edits, off-target events, and translocations with single-cell granularity.

This study compares FBS and human platelet lysate (HPL) for expanding CAR-Vδ2 T cells. Cells expanded in G-Rex with HPL showed greater expansion and in vivo anti-tumor activity. HPL reduction of cellular senescence and apoptosis pathways contributed to improved persistence compared to FBS.

This study investigated incorporating TLR4 signaling domains into CD19 CARs to improve efficacy against solid tumors. Primary T cells were transduced with CAR lentiviral vectors and expanded for 7-10 days in G-Rex six-well plates. The modified CAR-Ts exhibited enhanced cytotoxicity and cytokine secretion.

This review explores non-viral genetic modification methods for NK cells to produce off-the-shelf CAR-NK therapies. It highlights manufacturing strategies, noting that K562mbIL12-41BBL feeder cells facilitate large-scale expansion of peripheral blood NK cells in gas-permeable static cell culture (G-REX).

This study details the development of a CD22-targeted nanobody-based CAR-T therapy. Primary human T cells were transduced with CD22sdCAR lentivirus and expanded in G-Rex 10M. The 1ug36-sdCAR candidate demonstrated significant in vivo therapeutic activity and favorable tissue specificity in xenograft models.

The study evaluates GPR65 as a target. TCR-T cells (NY-ESO1 or MAGE-A4) were produced in G-Rex 6 Well Plate systems.

This study engineers memory T cells to secrete IDUA for treating MPS I. Engineered Tm cells were cultured and expanded in 24-well G-Rex tissue culture plates.

The study investigates EphA3-targeted CAR T cells for glioblastoma. T cells were transduced and expanded in G-Rex 24 well plates.

A review on NK cell expansion and improvement. It mentions G-Rex plates as a culture material used in protocols for expanding NK cells, specifically citing studies where G-Rex 6-well plates or G-Rex 100M vessels were used.

The study develops synNotch-programmed iPSC-NK cells to target CD155 and CD73 in glioblastoma. Cells were expanded for 2-3 weeks in G-Rex 24 well plates using NK Xpander medium.

This protocol details the expansion and gene repair of TSCM cells. It mentions that for scale-up and GMP-compliant experiments, electroporated TSCM can be expanded in G-Rex 100M gas-permeable culture vessels.

The paper describes a feeder-free method to generate AlloCAR-NKT cells from HSPCs. G-Rex 6M well plates were used for the expansion stage (stage 4) of the NKT cell culture.